Sandbox vidit
Cardioversion upto7 Days
Drug | Class of Recommendation/ Level of Evidence | Dosage | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Agents with proven efficacy | ||||||||||||
Dofetilide | I A |
| ||||||||||
Flecainide | I A | Oral: 200 to 300 mg Intravenous: 1.5 to 3.0 mg/kg over 10 to 20 min | ||||||||||
Ibutilide | I A | 1 mg over 10 min; repeat 1 mg when necessary | ||||||||||
Propafenone | I A | Oral: 600 mg Intravenous: 1.5 to 2.0 mg/kg over 10 to 20 min | ||||||||||
Amiodarone | IIa A | Oral:
Intravenous:
|
Cardioversion after 7 Days
Drug | Class of Recommendation/ Level of Evidence | Dosage | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Dofetilide | I A |
| ||||||||||
Amiodarone | IIa A | Oral:
Intravenous:
| ||||||||||
Ibutilide | IIa A | 1 mg over 10 min; repeat 1 mg when necessary |
Drugs which enhance the efficacy of cardioversion when given prior to the procedure: (Level of recommendation: IIa B)
- Amiodarone
- Flecainide
- Ibutilide
- Propafenone
- Sotalol
Drug Dosages for Maintenance of Sinus Rhythm
Following table summarizes the list of most commonly used drugs and their dosages for maintenance of sinus rhythm:
Drug | Dose |
---|---|
Amiodarone | 100 to 400 mg |
Disopyramide | 400 to 750 mg |
Dofetilide | 5000 to 1000 mcg |
Flecainide | 200 to 300 mg |
Procainamide | 1000 to 4000 mg |
Propafenone | 450 to 900 mg |
Quinidine | 600 to 1500 mg |
Sotalol | 160 to 320 mg |
Pharmacological Agents for Heart Rate Control
Drug | Class/LOE Recommendations | Loading Dose | Maintenance Dose |
---|---|---|---|
Acute Setting | |||
Heart rate control in patients without accessory pathway | |||
Esmolol | I C | 500 mcg/kg IV over 1 min | 60 to 200 mcg/kg/min IV |
Propanolol | I C | 0.15 mg/kg IV | NA |
Metoprolol | I C | 2.5 to 5 mg IV bolus over 2 min; up to 3 doses | NA |
Diltiazem | I B | 0.25 mg/kg IV over 2 min | 5 to 15 mg/h IV |
Verampil | I B | 0.075 to 0.15 mg/kg IV over 2 min | NA |
Heart Rate Control in patients with accessory pathway | |||
Amiodarone | IIa C | 150 mg over 10 min | 0.5 to 1 mg/min IV |
Heart Rate Control in patients with heart failure and without accessory pathway | |||
Digoxin | I B | 0.25 mg IV each 2 h, up to 1.5 mg | 0.125 to 0.375 mg daily IV or orally |
Amiodarone | IIa C | 150 mg over 10 min | 0.5 to 1 mg/min IV |
Non-Acute Setting and Chronic Maintenance Therapy | |||
Heart rate control | |||
Metoprolol | I C | Same as maintenance dose | 25 to 100 mg twice a day, orally |
Propanolol | I C | Same as maintenance dose | 80 to 240 mg daily in divided doses, orally |
Verampil | I B | Same as maintenance dose | 120 to 360 mg daily in divided doses; slow release available, orally |
Diltiazem | I B | Same as maintenance dose | 120 to 360 mg daily in divided doses; slow release available, orally |
Heart Rate Control in patients with heart failure and without accessory pathway | |||
Digoxin | I C | 0.5 mg by mouth daily | 0.125 to 0.375 mg daily, orally |
Amiodarone | IIb C | 800 mg daily for 1 wk, orally 600 mg daily for 1 wk, orally 400 mg daily for 4 to 6 wk, orally | 200 mg daily, orally |
CHADS2Scoring for Predicting Risk of Stroke
Condition | Points | |
---|---|---|
C | Congestive heart failure | |
H | Hypertension: blood pressure consistently above 140/90 mmHg (or treated hypertension on medication) |
|
A | Age >/=75 years | |
D | Diabetes Mellitus | |
S2 | Prior Stroke or TIA |
Anticoagulation is recommended for 3 wk prior to and 4 wk after cardioversion for patients with AF of unknown duration or with AF for longer than 48 h.